ContraFect Co. (NASDAQ:CFRX – Get Rating) was the recipient of a large growth in short interest in May. As of May 15th, there was short interest totalling 166,000 shares, a growth of 140.9% from the April 30th total of 68,900 shares. Currently, 4.6% of the company’s stock are sold short. Based on an average daily trading volume, of 3,970,000 shares, the days-to-cover ratio is presently 0.0 days.
Institutional Investors Weigh In On ContraFect
Several institutional investors and hedge funds have recently bought and sold shares of CFRX. Envestnet Asset Management Inc. acquired a new stake in ContraFect during the first quarter worth about $41,000. Dimensional Fund Advisors LP raised its stake in ContraFect by 62.9% during the first quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock worth $412,000 after acquiring an additional 43,564 shares during the period. Vanguard Group Inc. raised its stake in ContraFect by 0.7% during the first quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after acquiring an additional 11,064 shares during the period. State Street Corp raised its stake in ContraFect by 33.5% during the first quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after acquiring an additional 32,563 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in ContraFect by 1.2% during the first quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock worth $1,486,000 after acquiring an additional 4,948 shares during the period. Institutional investors and hedge funds own 27.34% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on CFRX shares. StockNews.com lowered shares of ContraFect from a “hold” rating to a “sell” rating in a report on Thursday. Maxim Group upgraded shares of ContraFect from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a report on Thursday, April 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $180.75.
ContraFect Stock Performance
ContraFect (NASDAQ:CFRX – Get Rating) last issued its earnings results on Friday, March 31st. The biotechnology company reported ($16.14) earnings per share (EPS) for the quarter. On average, equities analysts predict that ContraFect will post -15.39 earnings per share for the current year.
ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.
- Get a free copy of the StockNews.com research report on ContraFect (CFRX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.